| We have working groups with the Directorate-General for Public Health, the Directorate-General for Mental Health and Addictions, and the Directorate-General for Pharmacy of the Generalitat Valenciana [Valencia Regional Government]. | HIV
> HIV | Partenariato normativo
> Collaborazione con gli organismi di regolamentazione | 5000 | Local | Regularly | 119026705868 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Difesa del paziente
> Diritti del paziente | Partenariato normativo
> Collaborazione con gli organismi di regolamentazione | 10.000 | National | Sometimes | 119073823192 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Respiratorio
> Fibrosi polmonare | Partenariato normativo
> Collaborazione con gli organismi di regolamentazione | 1000 | National | Regularly | 119075356350 |
| IPT [Informe de Posicionamiento Terapéutico – Therapeutic Positioning Report]. | Neuromuscolare
> Duchenne | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 5000 | National | Regularly | 119045011464 |
| We participate in Health Technology Assessments for certain medicines. | Difesa del paziente
> Diritti del paziente | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | We do not communicate with patients directly | National | Rarely | 119049693177 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Difesa del paziente
> Diritti del paziente | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 10.000 | National | Sometimes | 119073823192 |
| We have recently completed IPT [Informe de Posicionamiento Terapéutico – Therapeutic Positioning Report] assessments for Anifrolumab [for adults with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE)] and Voclosporin [used to treat lupus nephritis].We are currently engaged in the IPT process for Obinutuzumab [used to treat specific blood cancers and active lupus nephritis]. | Reumatico
> Lupus | Partenariato normativo
> Partecipare alle valutazioni di Health Technology Assessment (HTA) e alle revisioni dei rimborsi | 100.000 | National | Regularly | 119076492282 |
| We are engaged with the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency of Medicines and Medical Devices] to advocate for access to innovative treatments. | Difesa del paziente
> Diritti del paziente | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | We do not communicate with patients directly | National | Regularly | 119012238994 |
| Community of Madrid, Department of Education, Department of Health. | Sanguinamento
> Disturbi emorragici: la maggior parte dei tipi | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | 5000 | Regional | Regularly | 119012535987 |
| We provide advisory input to government authorities on specific matters and regulatory provisions relating to our area of practice — the older adult population. | Persone anziane
> Persone anziane | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | We do not communicate with patients directly | National | Regularly | 119013803044 |
| Meetings with the Directorate-General for the Common Benefits Package and Pharmacy. | Raro
> Malattie rare: metaboliche/lisosomiali | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | 100 | National | Rarely | 119022231157 |
| We actively participate in meetings with the Ministry of Health, including with the HIV Control Division — covering viral hepatitis, tuberculosis, and other STIs [ITS, Infecciones de Transmisión Sexual – Sexually Transmitted Infections] — as well as with the Directorate-General for Pharmacy, among others. | HIV
> HIV | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | 100.000 | National | Regularly | 119036696548 |
| New therapeutic targets and State Health Council. | Reumatico
> Malattie reumatiche: la maggior parte dei tipi | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | 10.000 | National | Regularly | 119062924366 |
| Ministry of Health. | Cardiovascolare
> Condizioni cardiovascolari e cardiache | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | 5000 | National | Sometimes | 119072934071 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Difesa del paziente
> Diritti del paziente | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | 10.000 | National | Sometimes | 119073823192 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Respiratorio
> Fibrosi polmonare | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | 1000 | National | Regularly | 119075356350 |
| Not in my capacity as President of ACPA [Asociación Canaria de Pacientes - Canary Islands Patients’ Association], but rather as a member of the POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] Patient Platform and as President of Feasam [Federación de Asociaciones de Salud Mental de la Región de Murcia - Federation of Mental Health Associations of the Region of Murcia]. | Cardiovascolare
> Condizioni cardiovascolari e cardiache | Partenariato normativo
> Con altri sostenitori della salute | 100 | National | No | 119053738286 |
| Through ACCU [Asociaciones de Crohn y Colitis Ulcerosa - Crohn’s and Ulcerative Colitis Associations] Spain. | Gastrointestinale
> Gastrointestinale: altro | Partenariato normativo
> Con altri sostenitori della salute | 1000 | Regional | Sometimes | 119053970542 |
| FEDER [Federación Española de Enfermedades Raras – Spanish Federation of Rare Diseases] and EURORDIS [European Rare Disease Organisation]. | Raro
> Malattia di Wilson | Partenariato normativo
> Con altri sostenitori della salute | 100 | National | Regularly | 119078667611 |
| Legislation pertaining to patients living with a rare disease. | Raro
> Malattie rare: genetiche | Influenzare le politiche e la legislazione
> Influenzare le politiche sanitarie e la legislazione | 1000 | National | Regularly | 119012112198 |
| Legal, policy, institutional, and corporate actions. | Sicurezza del paziente
> Iatrogeno | Influenzare le politiche e la legislazione
> Influenzare le politiche sanitarie e la legislazione | 1000 | National | Regularly | 119045262726 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinale
> Celiaco | Influenzare le politiche e la legislazione
> Influenzare le politiche sanitarie e la legislazione | 100.000 | National | Regularly | 119053766557 |
| Letters were submitted to the Ministry of Health. | Raro
> Malattie rare: genetiche | Influenzare le politiche e la legislazione
> Influenzare le politiche sanitarie e la legislazione | 100 | National | Regularly | 119065350505 |
| In our country [Spain] it is challenging, but we do have channels through which we are able to communicate. | Fegato
> Malattie del fegato: trapianti | Influenzare le politiche e la legislazione
> Influenzare le politiche sanitarie e la legislazione | 5000 | National | Rarely | 119069515067 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Respiratorio
> Fibrosi polmonare | Influenzare le politiche e la legislazione
> Influenzare le politiche sanitarie e la legislazione | 1000 | National | Regularly | 119075356350 |
| Ongoing contact and coordination with César Hernández [Director General of the Common Portfolio of the NHS and Pharmacy within the Spanish Ministry of Health]. | Raro
> Malattie rare: la maggior parte dei tipi | Influenzare le politiche e la legislazione
> Influenzare le politiche sanitarie e la legislazione | 100.000 | National | Regularly | 119078056907 |
| In the Community of Madrid, we are consulted on medicines and their importance for our patient community. | Sanguinamento
> Disturbi emorragici: la maggior parte dei tipi | Influenzare le politiche e la legislazione
> Partecipa alle audizioni pubbliche e alle consultazioni | 5000 | Regional | Regularly | 119036712634 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Cronico
> Malattie croniche in generale | Influenzare le politiche e la legislazione
> Partecipa alle audizioni pubbliche e alle consultazioni | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinale
> Celiaco | Influenzare le politiche e la legislazione
> Partecipa alle audizioni pubbliche e alle consultazioni | 100.000 | National | Regularly | 119053766557 |
| We do not intervene in pricing decisions; however, we advocate for patient and stakeholder interests before the relevant public authorities. | Neurologico
> Sclerosi multipla | Influenzare le politiche e la legislazione
> Partecipa alle audizioni pubbliche e alle consultazioni | 5000 | Local | Regularly | 119064523376 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill (Proposición de Ley) and two Non-Legislative Motions (Proposiciones No de Ley) in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinale
> Celiaco | Influenzare le politiche e la legislazione
> Mobilitare parlamentari e leader politici | 100.000 | National | Regularly | 119053766557 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. We participate on a bimonthly basis in strategic meetings held with both the Regional Ministry of Health and the Regional Ministry of Equality and Social Services. | HIV
> HIV | Influenzare le politiche e la legislazione
> Mobilitare parlamentari e leader politici | 5000 | Local | Regularly | 119072832940 |
| Through the political action initiatives we undertake and promote. | Raro
> Malattie rare: genetiche | Influenzare le politiche e la legislazione
> Mobilitare parlamentari e leader politici | 100 | International | Regularly | 119078207611 |
| Legislation pertaining to patients living with a rare disease. | Raro
> Malattie rare: genetiche | Influenzare le politiche e la legislazione
> Sostenere le leggi e i diritti per la protezione dei pazienti | 1000 | National | Regularly | 119012112198 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill (Proposición de Ley) and two Non-Legislative Motions (Proposiciones No de Ley) in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinale
> Celiaco | Influenzare le politiche e la legislazione
> Contribuire alla redazione della legislazione in materia di salute pubblica | 100.000 | National | Regularly | 119053766557 |
| Our objective is to advocate for the approval of all pancreatic cancer-related medicines in Spain. | Cancro
> Cancro: pancreatico | Influenzare le politiche e la legislazione
> Affrontare barriere/anomalie nell'assistenza medica | 1000 | National | Rarely | 119012120290 |
| Nucleoside therapy for TK2d has recently received approval from the EMA [European Medicines Agency] and the FDA [Food and Drug Administration], so the next phase will be price regulation. | Raro
> Malattie rare: genetiche | Advocacy per prezzi e accessibilità economica
> Sostenere prezzi equi dei farmaci | 100 | National | Regularly | 119070360428 |
| Reimbursement of biological treatments. | Respiratorio
> BPCO | Advocacy per prezzi e accessibilità economica
> Sostenere prezzi equi dei farmaci | 1000 | National | Regularly | 119078128994 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Cronico
> Malattie croniche in generale | Advocacy per prezzi e accessibilità economica
> Partecipare alle negoziazioni del comitato di revisione dei prezzi | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Nucleoside therapy for TK2d [Thymidine Kinase 2 deficiency] has recently received approval from the EMA [European Medicines Agency] and the FDA [Food and Drug Administration], so the next phase will be price regulation. | Raro
> Malattie rare: genetiche | Advocacy per prezzi e accessibilità economica
> Partecipare alle negoziazioni del comitato di revisione dei prezzi | 100 | National | Regularly | 119070360428 |
| Meetings with the Directorate-General for the Common Benefits Package and Pharmacy. | Raro
> Malattie rare: metaboliche/lisosomiali | Advocacy per prezzi e accessibilità economica
> Sostenere l'inclusione del prodotto negli elenchi di rimborso/formulari nazionali | 100 | National | Rarely | 119022231157 |
| The priority is not so much determining the price, but securing reimbursement. | Respiratorio
> Respiratorio: la maggior parte delle condizioni | Advocacy per prezzi e accessibilità economica
> Sostenere l'inclusione del prodotto negli elenchi di rimborso/formulari nazionali | 5000 | National | Regularly | 119054105408 |
| … Reimbursement of biological therapies. | Respiratorio
> BPCO | Advocacy per prezzi e accessibilità economica
> Sostenere l'inclusione del prodotto negli elenchi di rimborso/formulari nazionali | 1000 | National | Regularly | 119078128994 |
| Our objective is to advocate for the approval of all pancreatic cancer-related medicines in Spain. | Cancro
> Cancro: pancreatico | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | 1000 | National | Rarely | 119012120290 |
| We are engaged with the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency of Medicines and Medical Devices] to advocate for access to innovative treatments. | Difesa del paziente
> Diritti del paziente | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | We do not communicate with patients directly | National | Regularly | 119012238994 |
| We participate in the sampling of products entering public tender processes. | Endocrino
> Diabete (sia di tipo 1 che di tipo 2) | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | 5000 | Regional | Regularly | 119019803062 |
| We successfully halted the withdrawal of public reimbursement for SYSADOAs [Symptomatic Slow-Acting Drugs for Osteoarthritis], an effective and well-established treatment for osteoarthritis. | Osso
> Osteoartrite e Osteoporosi | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | 5000 | National | Regularly | 119022568142 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Cronico
> Malattie croniche in generale | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Removal of the prior authorisation requirement for triple therapy [Doctors in Spain needed administrative approval from the National Health System to prescribe or fully reimburse a combined respiratory drug in a single inhaler.] | Respiratorio
> BPCO | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | 1000 | National | Regularly | 119078128994 |
| Providing guidance from the patient perspective. | Raro
> Malattie rare: la maggior parte dei tipi | Contributo del paziente basato sull'evidenza
> Utilizza le informazioni sui pazienti per prendere decisioni informate | 1000 | National | Regularly | 119055416525 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Difesa del paziente
> Diritti del paziente | Contributo del paziente basato sull'evidenza
> Utilizza le informazioni sui pazienti per prendere decisioni informate | 10.000 | National | Sometimes | 119073823192 |
| They consult us. | Neurologico
> Fibromialgia | Contributo del paziente basato sull'evidenza
> Utilizza le informazioni sui pazienti per prendere decisioni informate | Do not know | Local | Sometimes | 119075536668 |
| ... Advise from the patient's perspective. Influence through formal participation or institutional pressure. Contribute social evidence and patient experience. Contributing real-world evidence and patient experience. | Raro
> Malattie rare: la maggior parte dei tipi | Contributo del paziente basato sull'evidenza
> Fornire prove del mondo reale (RWE) alle agenzie regolatorie | 1000 | National | Regularly | 119055416525 |
| ... Contributing real-world evidence and patient experience. | Raro
> Malattie rare: la maggior parte dei tipi | Contributo del paziente basato sull'evidenza
> Sfrutta le storie dei pazienti e le narrazioni basate sull'esperienza vissuta | 1000 | National | Regularly | 119055416525 |
| Associations of family members of patients with Alzheimer's disease [interacting with drug regulators]. | Neurodegenerativo
> Alzheimer | Contributo del paziente basato sull'evidenza
> Sfrutta le storie dei pazienti e le narrazioni basate sull'esperienza vissuta | We do not communicate with patients directly | Regional | Regularly | 119067801531 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Cronico
> Malattie croniche in generale | Contributo del paziente basato sull'evidenza
> Tradurre prove e approfondimenti in contributi politici | We do not communicate with patients directly | National | Regularly | 119052165521 |
| … We raise concerns on issues such as adverse drug reactions. | Persone anziane
> Persone anziane | Diagnosi e consegna dei medicinali
> Garantire un uso sicuro ed efficace dei farmaci | We do not communicate with patients directly | National | Regularly | 119013803044 |
| By providing information on the indications for which administration of the orphan medicinal product is clearly necessary, as well as the circumstances in which alternative forms of healthcare provision may be expected or appropriate. | Raro
> Sindrome di Von Hippel-Lindau | Diagnosi e consegna dei medicinali
> Garantire un uso sicuro ed efficace dei farmaci | 100 | National | Rarely | 119046844450 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Difesa del paziente
> Diritti del paziente | Diagnosi e consegna dei medicinali
> Garantire un uso sicuro ed efficace dei farmaci | 10.000 | National | Sometimes | 119073823192 |
| … We also issue practice recommendations for members of the ESGG [Sociedad Española de Geriatría y Gerontología – Spanish Society of Geriatrics and Gerontology]. | Persone anziane
> Persone anziane | Diagnosi e consegna dei medicinali
> Partecipare allo sviluppo di linee guida cliniche | We do not communicate with patients directly | National | Regularly | 119013803044 |
| We provide advisory input to government authorities on specific matters and regulatory provisions relating to our area of practice — the older adult population. | Persone anziane
> Persone anziane | Governance istituzionale
> Garantire la rappresentanza negli organi consultivi governativi | We do not communicate with patients directly | National | Regularly | 119013803044 |
| With public authorities. | Sanguinamento
> Emofilia | Governance istituzionale
> Garantire la rappresentanza negli organi consultivi governativi | 100 | Regional | Regularly | 119053275561 |
| Not directly through ACPA [Asociación Comarcal de Personas con Ansiedad - Regional Association of People with Anxiety], but through Rafael Martínez in his capacity as President of FEASAM [Federación de Asociaciones de Salud Mental de la Región de Murcia - Federation of Mental Health Associations of the Region of Murcia] and as a member of the POP [Patients’ Organisations Platform - Plataforma de Organizaciones de Pacientes] Patient Platform. | Cardiovascolare
> Condizioni cardiovascolari e cardiache | Governance istituzionale
> Garantire la rappresentanza negli organi consultivi governativi | 100 | Local | No | 119053750627 |
| Providing guidance from the patient perspective. Exercising influence through formal participation or institutional advocacy. | Raro
> Malattie rare: la maggior parte dei tipi | Governance istituzionale
> Garantire la rappresentanza negli organi consultivi governativi | 1000 | National | Regularly | 119055416525 |
| We do not intervene in pricing decisions; however, we do represent and defend the interests of those we advocate for before the relevant public authorities. | Neurologico
> Sclerosi multipla | Governance istituzionale
> Garantire la rappresentanza negli organi consultivi governativi | 5000 | Local | Regularly | 119064523376 |
| We represent the interests of patients, but we do not intervene in pricing decisions. | Neurologico
> Sclerosi multipla | Governance istituzionale
> Garantire la rappresentanza negli organi consultivi governativi | 10.000 | Regional | Rarely | 119065344758 |
| We are members of the Patient Committee of the Valencian Community. | HIV
> HIV | Governance istituzionale
> Garantire la rappresentanza negli organi consultivi governativi | 10.000 | Regional | No | 119072419533 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. We participate on a bimonthly basis in strategic meetings held with both the Regional Ministry of Health and the Regional Ministry of Equality and Social Services. | HIV
> HIV | Governance istituzionale
> Garantire la rappresentanza negli organi consultivi governativi | 5000 | Local | Regularly | 119072832940 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Difesa del paziente
> Diritti del paziente | Governance istituzionale
> Garantire la rappresentanza negli organi consultivi governativi | 10.000 | National | Sometimes | 119073823192 |
| The organisation has held Public Interest status, as designated by the Spanish Ministry of the Interior, since 2008. | Neurologico
> Neurologico: la maggior parte delle condizioni | Governance istituzionale
> Mantenere lo status formale di ente di interesse pubblico o di beneficenza | 1000 | Local | Rarely | 119054524092 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. | HIV
> HIV | Governance istituzionale
> Mantenere lo status formale di ente di interesse pubblico o di beneficenza | 5000 | Local | Regularly | 119072832940 |
interazioni
azioni e advocacy
19 menzioni
